Associated Papers
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Clinical pharmacogenetic analysis in 5,001 individuals with diagnostic Exome Sequencing data.
Lanillos J et al.
Npj Genomic Medicine, 2022
Identification of pharmacogenetic variants from large scale next generation sequencing data in the Saudi population.
Goljan E et al.
Plos One, 2022
Frequency of Important CYP450 Enzyme Gene Polymorphisms in the Iranian Population in Comparison with Other Major Populations: A Comprehensive Review of the Human Data.
Neyshaburinezhad N et al.
Journal of Personalized Medicine, 2021
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects.
Zhou Y et al.
Clinical Pharmacology and Therapeutics, 2017
Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.
Hiratsuka M
Biological & Pharmaceutical Bulletin, 2016
Functional characterization of 32 CYP2C9 allelic variants.
Niinuma Y et al.
The Pharmacogenomics Journal, 2014
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Polymorphisms of human cytochrome P450 2C9 and the functional relevance.
Zhou SF et al.
Toxicology, 2010
Genetic and clinical factors relating to warfarin dosing.
Jonas DE et al.
Trends in Pharmacological Sciences, 2009
Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?
Agúndez JA et al.
Expert Opinion on Drug Metabolism & Toxicology, 2009
Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese.
Maekawa K et al.
Pharmacogenetics and Genomics, 2006
Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.
Daly AK et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals.
García-Martín E et al.
Molecular Diagnosis & Therapy, 2006
CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
Allabi AC et al.
Pharmacogenetics and Genomics, 2005
Discovery of new potentially defective alleles of human CYP2C9.
Blaisdell J et al.
Pharmacogenetics, 2004